Pioneering Medical Innovations
Imperative Care launched the Ikon 24 Pro Guidewire, enhancing the Zoom Stroke System to support more efficient stroke procedures.
A new analysis of the SYMPHONY-PE Trial suggests early thrombectomy may improve key measures of heart recovery in intermediate-risk pulmonary embolism patients.
Jay Martin was appointed Chief Commercial Officer of Imperative Care.
Imperative Care initiated the ADAPT 2.0 study evaluating an advanced clinical technique designed to simplify acute ischemic stroke treatment.
The company initiated the CLEAR-IT clinical study targeting gaps in clinical standards for peripheral thromboembolism.
Imperative Care announced $100 million in financing to support continued growth and innovation in thromboembolic disease care.
Imperative Care launched the Zoom 4S Catheter, further expanding the Zoom Stroke System.
Late-breaking, real-world data from a multi-center review of stroke patients treated with the ADAPT 2.0 technique using the Zoom Stroke System were presented at the SVIN 2025 annual meeting.
Positive efficacy and safety results from the pivotal SYMPHONY-PE Trial were presented at The PERT Consortium symposium and published in Circulation: Cardiovascular Interventions, with no mortality and no device-related serious adverse events.
The FDA cleared the Symphony Thrombectomy System, the first large-bore continuous vacuum system for treating pulmonary embolism.